Guide
Biotech-Pharma: international regulatory cooperation
Nicolas Panzer, Senior Manager Life Sciences
Jun 17, 2026
For Swiss pharmaceutical manufacturers, entering foreign markets involves substantial regulation: site inspections, dossier reviews and ongoing oversight, all of which are conducted in accordance with the destination market's rules.
A set of international agreements and cooperation mechanisms reduces the duplication that would otherwise be required. They do not replace national approval, as each market continues to authorise its own medicines. However, they allow authorities to build on one another's work in specific areas, thereby reducing timelines and administrative costs.
Why these mechanisms matter for exporters
International regulatory cooperation reduces two of the main fixed costs in cross-border pharmaceutical trade: duplicate GMP inspections and parallel dossier reviews. Where these mechanisms apply, manufacturers face fewer overlapping audits, shorter approval timelines and more predictable interactions with foreign authorities.
The frameworks at a glance
Switzerland's framework for international regulatory cooperation in pharmaceuticals rests on four mechanisms, each addressing a different element.
| Agreement type | Mechanism | Regulatory objective | Participating countries / authorities |
| Bilateral GMP MRAs | Mutual recognition of inspections and manufacturing authorizations | Duplicate GMP inspections | Canada, South Korea, UK, US |
| EU framework under Chapter 15 of the EU-Switzerland MRA | Mutual recognition of inspections, manufacturing authorizations and batch certification | Duplicate GMP inspections and facilitate batch release | EU states |
| EFTA framework under Annex I to the EFTA Convention | Mutual recognition of GMP inspections and manufacturing authorizations | Duplicate GMP oversight | EFTA states |
| PIC/S | Multilateral inspection cooperation based on shared GMP standards | Mutual reliance on inspections through shared GMP standards | Approximately 50 inspectorates, including Australia, Japan, Singapore, Taiwan and Malaysia |
| Access Consortium | Coordinated assessment of marketing authorization applications | Australia, Canada, Singapore, UK, Switzerland |
The Access Consortium: coordinated product approval
The Access Consortium addresses the product approval stage of market access. It is a work-sharing initiative between five medicines regulators: Swissmedic, Health Canada, the TGA (Australia), HSA (Singapore) and the MHRA (UK).
Companies submitting an application to at least two member agencies in parallel can have the scientific review conducted jointly, with the participating authorities sharing the assessment and aligning where possible on questions and outcomes. Work-sharing pathways exist for new active substances, generic medicines and biosimilars. Each authority continues to issue its own national authorization, but the scientific evaluation is largely consolidated, reducing the number of independent review cycles and shortening the overall time to approval.
The geographic overlap with the inspection-side mechanisms is substantial: for a Swiss company entering Canada, the UK, Australia or Singapore, the Access Consortium handles the dossier review while the bilateral MRA (Canada, UK) or PIC/S reliance (Australia, Singapore) addresses the inspection side. The dossier-review effect is often the larger of the two in commercial terms, as it directly affects time to first authorization.
Bilateral GMP mutual recognition agreements
Bilateral GMP MRAs allow each authority to recognize the GMP inspection results and manufacturing authorizations issued by its counterpart, within the scope defined by the agreement.
Canada
The Canada agreement goes further than most. It recognizes not only GMP certificates but also the manufacturer's batch certification, so batches do not need to be re-tested on import. It is also the most developed of the four arrangements, with established mechanisms for cooperation between the two authorities.
For Swiss pharmaceutical manufacturers, Canada is attractive not only because of its market environment, but also because predictable regulatory processes matter in day-to-day operations. That combination can make market development more manageable.
Korea
The agreement with South Korea is more streamlined. Both sides treat each other's GMP oversight as equivalent, supported by their shared PIC/S membership. They rely on each other's GMP certificates, inspection reports and CAPA (corrective and preventive action) information, but can still conduct their own inspections if needed. It covers a wide range of human medicines, including investigational products, APIs, biopharmaceuticals and herbal medicines.
Korea has become a leading Asian biopharma market, with strong capabilities in biosimilars, CMO/CDMO services and large-scale biomanufacturing. For Swiss biotech-pharma companies, it offers opportunities in a market that values quality, technical credibility, advanced research networks and reliable international partnerships.
Andrea Clementi
Head of Swiss Business Hub Korea
United Kingdom
The UK arrangement provides continuity after Brexit by carrying the relevant Switzerland–EU architecture over into the bilateral trade agreement. For exporters, it operates more as a means of preserving an existing regulatory framework than as a new inspection model.
The United Kingdom ranks among Europe’s most important pharmaceutical markets, with a mature ecosystem spanning research, manufacturing, and healthcare delivery. For Swiss companies, it offers relevant potential for both established products and specialized offerings.
Natalie Thomas
Head Swiss Business Hub UK
United States
The US agreement is the most detailed of the four and sets out clearly which GMP documents may be accepted and where the limits of recognition lie. It currently applies to routine surveillance inspections and covers a wide range of pharmaceuticals and APIs, with explicit exclusions for advanced therapy medicinal products, human blood, plasma, tissues, organs and cells, and veterinary immunologicals; vaccines for human use may be added at a later stage.
For Swiss exporters, the U.S. is attractive because of its scale, diversity, and ability to reward differentiated products. At the same time, it is a market where clarity on regulatory scope and operational readiness can make a real difference.
Florin Müller
Head of Swiss Business Hub USAThe EU and EFTA framework
GMP inspection recognition and batch certification for medicinal products between Switzerland and the EU continue to operate under Chapter 15 of the Switzerland–EU Mutual Recognition Agreement. The wider MRA has not been updated since 2021, and the medical devices chapter has lapsed. The pharmaceutical chapter remains operational, but its long-term status is linked to the broader evolution of the Switzerland–EU relationship and is therefore subject to monitoring. Within EFTA, recognition operates through the association's own arrangements, with effects comparable to those under the EU framework.
PIC/S: multilateral inspection cooperation
A significant share of Switzerland's effective inspection recognition does not rest on a bilateral MRA. Through Swissmedic's membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S), an international network of approximately 50 inspectorates, Swiss GMP evidence is accepted in jurisdictions that apply equivalent inspection standards.
Australia is a representative example. The Therapeutic Goods Administration (TGA) accepts Swissmedic GMP certificates through its GMP Clearance / Compliance Verification pathway on the basis of shared PIC/S membership, rather than under a bilateral MRA. Comparable reliance applies in Japan, Singapore, Malaysia, Taiwan and other PIC/S jurisdictions. The legal basis differs from a formal MRA, but the practical effect, namely the avoidance of duplicate inspections, can be similar. But is important to state that PIC/S membership does not by itself create an automatic obligation to accept another member's GMP evidence.
How the mechanisms work in practice
All four mechanisms operate on the principle of regulatory reliance: one authority draws on the work of another rather than repeating it. For GMP MRAs, this applies to inspection outcomes and manufacturing authorizations issued by the partner's competent authority, and may in some cases extend to inspections of third-country manufacturers conducted by the partner authority. For the Access Consortium, reliance applies to the scientific assessment of the dossier. Regulatory oversight remains in place throughout; what changes is the volume of duplicative work required to satisfy it across markets.
For an export-driven economy like Switzerland, regulatory cooperation is a precondition for market access. Every agreement cuts duplication, shortens time to market and strengthens the competitiveness of our pharma industry abroad."
Nicolas Panzer
Senior Manager Life SciencesWhat are the limits?
None of the four mechanisms grants automatic market access. A GMP MRA does not constitute a marketing authorization. PIC/S reliance addresses inspections only. The Access Consortium delivers a coordinated review, but each national authority issues its own decision. National rules on labeling, pricing, reimbursement and post-market surveillance continue to apply in every destination market. The combined effect of the four mechanisms is therefore narrower than each individual headline suggests, but materially greater than any one of them in isolation.
What is the outlook?
For Swiss pharmaceutical exporters, the international cooperation framework is comparatively favorable. Between bilateral GMP MRAs, the EU/EFTA framework, PIC/S-based inspection reliance and the Access Consortium's joint review pathways, Swissmedic-backed evidence is recognized, formally or in practice, across most of Switzerland's major export markets. The value of each mechanism depends on its scope, its current operational status, and the specifics of the product and site involved. The principal practical risk for exporters lies less in the absence of a pathway than in the selection of the correct mechanism for a given market.
Disclaimer: The information presented on this page has been gathered and researched from sources believed to be reliable and is written in good faith. Switzerland Global Enterprise cannot be held liable for data that may not be complete, accurate or up-to-date, nor for data that originates from Internet sites/sources over which Switzerland Global Enterprise has no control. The information on this page does not have a legal or juridical character. For individual advice, please contact Switzerland Global Enterprise.
